Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03929666
Title A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Zymeworks Inc.
Indications

colorectal cancer

gastroesophageal adenocarcinoma

biliary tract cancer

Therapies

Cisplatin + Gemcitabine

Cisplatin + Fluorouracil + ZW25

Capecitabine + Oxaliplatin + ZW25

Fluorouracil + Leucovorin + Oxaliplatin + ZW25

Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + ZW25

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.